ArticleArchives of medical sciences. Atherosclerotic diseases2025

Pioglitazone with SGLT2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes and non-alcoholic fatty liver disease: could the combinations of an old friend with new players yield better outcomes?

Georgios S Papaetis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.